Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib

被引：3
|
作者：
Sigmund, Audrey M. [1 ]
Huang, Ying [1 ]
Ruppert, Amy S. [1 ]
Maddocks, Kami [1 ]
Rogers, Kerry A. [1 ]
Jaglowski, Samantha [1 ]
Bhat, Seema A. [1 ]
Kittai, Adam S. [1 ]
Grever, Michael R. [1 ]
Byrd, John C. [1 ,2 ]
Woyach, Jennifer A. [1 ]
机构：
[1] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA
[2] Univ Cincinnati, Dept Internal Med, Cincinnati, OH USA
来源：
LEUKEMIA | 2022年 / 36卷 / 08期
关键词：
OFATUMUMAB; THERAPY; DISEASE; BTK;
D O I：
10.1038/s41375-022-01640-y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：2129 / 2131
页数：3
相关论文
共 50 条
  • [21] LEUKOCYTE DOUBLING TIME IS A USEFUL PREDICTOR OF PROGRESSION-FREE SURVIVAL IN CHRONIC LYMPHOCYTIC-LEUKEMIA
    AXDORPH, U
    NILSSON, BI
    NILSSON, BR
    BJORKHOLM, M
    [J]. JOURNAL OF INTERNAL MEDICINE, 1995, 237 (02) : 205 - 209
  • [22] Partial response or better at six months is prognostic of superior progression-free survival in Waldenstrom macroglobulinaemia patients treated with ibrutinib
    Castillo, Jorge J.
    Abeykoon, Jithma P.
    Gustine, Joshua N.
    Zanwar, Saurabh
    Mein, Kirsten
    Flynn, Catherine A.
    Demos, Maria G.
    Guerrera, Maria L.
    Kofides, Amanda
    Liu, Xia
    Munshi, Manit
    Tsakmaklis, Nickolas
    King, Rebecca
    Yang, Guang
    Hunter, Zachary R.
    Advani, Ranjana H.
    Palomba, Maria Lia
    Ansell, Stephen M.
    Gertz, Morie A.
    Kapoor, Prashant
    Treon, Steven P.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (03) : 542 - 550
  • [23] Partial response or better at 6 months is prognostic of superior progression-free survival in patients with Waldenstrom macroglobulinaemia treated with ibrutinib
    Vitolo, Umberto
    Novo, Mattia
    Santambrogio, Elisa
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2021, 192 (03) : 423 - 424
  • [24] Association between Quality of Response and Outcome in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
    Strati, Paolo
    Sivina, Mariela
    Kim, Ekaterina
    Keating, Michael J.
    Wierda, William G.
    Ferrajoli, Alessandra
    Kantarjian, Hagop M.
    Estrov, Zeev E.
    Jain, Nitin
    Thompson, Philip A.
    Burger, Jan A.
    [J]. BLOOD, 2018, 132
  • [25] Autoimmune cytopenias in patients with chronic lymphocytic leukemia treated with ibrutinib
    Vitale, Candida
    Ahn, Inhye E.
    Sivina, Mariela
    Ferrajoli, Alessandra
    Wierda, William G.
    Estrov, Zeev
    Konoplev, Sergej N.
    Jain, Nitin
    O'Brien, Susan
    Farooqui, Mohammed
    Keating, Michael J.
    Wiestner, Adrian
    Burger, Jan A.
    [J]. HAEMATOLOGICA, 2016, 101 (06) : E254 - E258
  • [26] Mcl-1 as a Possible Predictor of Progression-Free Survival in Previously Untreated Chronic Lymphocytic Leukemia Patients Treated with Pentostatin, Cyclophosphamide and Rituximab
    Awan, Farrukh
    Kay, Neil E.
    Davis, Melanie
    Wu, Wenting
    Leung, Nelson
    Jelinek, Diane F.
    Tschumper, Renee
    Secreto, Charla
    Lin, Thomas S.
    Grever, Michael R.
    Shanafelt, Tait
    Zent, Clive S.
    Call, Timothy G.
    Heerema, Nyla A.
    Lozanski, Gerard
    Byrd, John C.
    Lucas, David
    [J]. BLOOD, 2008, 112 (11) : 732 - 733
  • [27] Relationship between progression-free survival and overall survival in chronic lymphocytic leukemia: a literature-based analysis
    Beauchemin, C.
    Johnston, J. B.
    Lapierre, M. E.
    Aissa, F.
    Lachaine, J.
    [J]. CURRENT ONCOLOGY, 2015, 22 (03) : E148 - E156
  • [28] Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
    Hampel, Paul J.
    Rabe, Kari G.
    Call, Timothy G.
    Ding, Wei
    Leis, Jose F.
    Chanan-Khan, Asher A.
    Kenderian, Saad S.
    Muchtar, Eli
    Wang, Yucai
    Ailawadhi, Sikander
    Koehler, Amber B.
    Parrondo, Ricardo
    Schwager, Susan M.
    Sher, Taimur
    Hanson, Curtis A.
    Shi, Min
    Van Dyke, Daniel L.
    Braggio, Esteban
    Slager, Susan L.
    Kay, Neil E.
    Parikh, Sameer A.
    [J]. BLOOD CANCER JOURNAL, 2022, 12 (09)
  • [29] Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
    Paul J. Hampel
    Kari G. Rabe
    Timothy G. Call
    Wei Ding
    Jose F. Leis
    Asher A. Chanan-Khan
    Saad S. Kenderian
    Eli Muchtar
    Yucai Wang
    Sikander Ailawadhi
    Amber B. Koehler
    Ricardo Parrondo
    Susan M. Schwager
    Taimur Sher
    Curtis A. Hanson
    Min Shi
    Daniel L. Van Dyke
    Esteban Braggio
    Susan L. Slager
    Neil E. Kay
    Sameer A. Parikh
    [J]. Blood Cancer Journal, 12
  • [30] The addition of bevacizumab to chemoimmunotherapy prolongs progression-free survival in patients with chronic lymphocytic leukemia (CLL) through modulation of the microenvironment
    Strati, Paolo
    Shanafelt, Tait D.
    Laplant, Betsy
    Pettinger, Adam
    Lesnick, Connie
    Nikcevich, Daniel
    Call, Timothy
    Ding, Wei
    Hanson, Curtis
    Kay, Neil
    [J]. CANCER RESEARCH, 2016, 76
12345